Dr John Bashford, research director at the Icon Group, spoke with BioPharmaDispatch about its approach to cancer care and clinical trials using targeted therapy and immunotherapy.
![](https://e76bb9fd1f54a7a912eb-40f6ec802f763655ee14c32dfe77820e.ssl.cf4.rackcdn.com/0072e556cee697544a697eef007051be.png)
Latest Video
New Stories
-
ENA respiratory secures extension of US funding for novel prophylactic antiviral
September 8, 2024 - - Latest News -
Groups welcome wider access to shingles vaccine for immunocompromised patients
September 6, 2024 - - Latest News -
CSL announces sale of Wuhan plasma collection and fractionation operations
September 5, 2024 - - Latest News -
The 'Week in Review' Podcast - 6 September
September 5, 2024 - - Podcast -
Pfizer-backed initiative boosts Aboriginal and Torres Strait Islander pharmacy leadership
September 5, 2024 - - Latest News -
An increasingly busy ministerial agenda risks squeezing out other issues
September 5, 2024 - - Latest News -
Groups collaborate on the development of new opioid safety toolkit
September 5, 2024 - - Latest News